120 related articles for article (PubMed ID: 23564824)
1. Expression of MAGE A1-6 and the clinical characteristics of papillary thyroid carcinoma.
Lee HS; Kim SW; Hong JC; Jung SB; Jeon CH; Park JW; Park SY; Lee KD
Anticancer Res; 2013 Apr; 33(4):1731-5. PubMed ID: 23564824
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of MAGE A1-6 RT-nested PCR for diagnosis of lung cancer invisible by bronchoscopy.
Shin KC; Choi EY; Chung JH; Jeon C; Lee KH
Anticancer Res; 2012 Jan; 32(1):163-7. PubMed ID: 22213302
[TBL] [Abstract][Full Text] [Related]
3. Melanoma antigen-1 mRNA combined with alpha-fetoprotein mRNA levels in peripheral blood of patients with hepatocellular carcinoma: a predictor of postoperative recurrence or metastasis?
Zhang Y; Song T; Meng L; Wu X; Ba Y; Li Q
ANZ J Surg; 2009; 79(1-2):62-9. PubMed ID: 19183381
[TBL] [Abstract][Full Text] [Related]
4. Papillary thyroid carcinoma in pregnancy: a variant of the disease?
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill AJ; Gundara JS; Ip J; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Ann Surg Oncol; 2012 Dec; 19(13):4210-6. PubMed ID: 22875646
[TBL] [Abstract][Full Text] [Related]
5. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
6. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
7. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
8. Expression of melanoma-associated antigens in oral squamous cell carcinoma.
Ries J; Vairaktaris E; Mollaoglu N; Wiltfang J; Neukam FW; Nkenke E
J Oral Pathol Med; 2008 Feb; 37(2):88-93. PubMed ID: 18197853
[TBL] [Abstract][Full Text] [Related]
9. Molecular prognosticators and genomic instability in papillary thyroid cancer.
Rigual NR; Anderson GR; Loree TR; Wiseman S; Alrawi S; Stoler DL
Laryngoscope; 2005 Aug; 115(8):1479-85. PubMed ID: 16094129
[TBL] [Abstract][Full Text] [Related]
10. Expression of MAGE A 1-6 mRNA in sputa of head and neck cancer patients--a preliminary report.
Lee KD; Lee HH; Joo HB; Lee HS; Yu TH; Chang HK; Jeon CH; Park JW
Anticancer Res; 2006; 26(2B):1513-8. PubMed ID: 16619566
[TBL] [Abstract][Full Text] [Related]
11. The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma.
Kwon S; Kang SH; Ro J; Jeon CH; Park JW; Lee ES
Cancer; 2005 Jul; 104(2):251-6. PubMed ID: 15937912
[TBL] [Abstract][Full Text] [Related]
12. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
Howell GM; Carty SE; Armstrong MJ; Lebeau SO; Hodak SP; Coyne C; Stang MT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
Ann Surg Oncol; 2011 Dec; 18(13):3566-71. PubMed ID: 21594703
[TBL] [Abstract][Full Text] [Related]
13. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
14. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Dai L; Wang Y; Chen L; Zheng J; Li J; Wu X
World J Surg Oncol; 2017 Jan; 15(1):11. PubMed ID: 28061868
[TBL] [Abstract][Full Text] [Related]
15. A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer.
Mecklenburg I; Weckermann D; Zippelius A; Schoberth A; Petersen S; Prang N; Riethmüller G; Kufer P
J Immunol Methods; 2007 Jun; 323(2):180-93. PubMed ID: 17540401
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
17. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
18. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
19. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
20. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
